Investors Alert: Hims & Hers Faces Class Action Lawsuit Risks

Investigation of Securities Fraud at Hims & Hers Health
PHILADELPHIA, July 28, 2025 -- Berger Montague, a prominent law firm specializing in securities litigation, is actively investigating Hims & Hers Health Inc. (NYSE: HIMS) for potential securities fraud. This investigation focuses on the period from April 29, 2025, to June 22, 2025, where Hims & Hers may have violated federal securities laws by misleading investors through false statements.
Significant Stock Price Drop
On June 23, 2025, the stock of Hims & Hers experienced a dramatic decline of over 34%. This plummet occurred after a major announcement from Novo Nordisk, revealing that it had terminated its partnership with Hims due to complaints regarding the company's unauthorized marketing and sale of compounded semaglutide drugs. The revelation has led to concerns about material misstatements and omissions, prompting legal action.
Deadline for Lead Plaintiff Applications
Investors who have suffered losses during the designated Class Period have until August 25, 2025, to apply for lead plaintiff status in the class-action lawsuit. The lead plaintiffs play a crucial role in directing the case and representing the interests of fellow investors who have also been affected.
How to Get Involved
If you're an investor in Hims & Hers, it's essential to understand your rights and potential courses of action. For assistance, you can reach out to Berger Montague. Andrew Abramowitz, a senior counsel, is available at (215) 875-3015, or you can contact Caitlin Adorni at (267) 764-4865.
About Berger Montague
Founded in 1970, Berger Montague has established itself as a leader in securities class action litigation. With offices across multiple regions, the firm has represented countless individual and institutional investors over the decades. Their experience equips them to handle complex securities fraud cases effectively.
Contact Information
To learn more about the ongoing investigation and your potential involvement, reach out to:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com
Caitlin Adorni
Berger Montague
(267) 764-4865
cadorni@bergermontague.com
Frequently Asked Questions
What is the reason for the class action against Hims & Hers?
The class action is prompted by significant stock price drops following allegations of securities fraud.
What is the deadline to pursue claims?
Investors must act by August 25, 2025, to be eligible to become lead plaintiffs in the lawsuit.
Who can join the class action?
Any investor who purchased shares during the Class Period and suffered losses may join.
How can I contact Berger Montague?
Investors can contact Andrew Abramowitz or Caitlin Adorni via phone or email for more information.
What constitutes securities fraud?
Securities fraud involves misleading investors, making false statements, or omitting key information about a company's performance.
About The Author
Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.